Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy

Journal of Immunotherapy

Volumn 31, Issue 7, 2008, Pages 665-674

  Fujita, Yuriko ^a   Leen, Ann M ^a,b   Sun, Jiali ^a,c   Nakazawa, Yozo ^a   Yvon, Eric ^a   Heslop, Helen E ^a,b,d   Brenner, Malcolm K ^a,b,d   Rooney, Cliona M ^a,b,c,e,f  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b Departments of Pediatrics   (United States)

^c Departments of Immunology   (United States)

^d Departments of Medicine   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

IFN g selection; Immunotherapy; Stem cell transplantation; Viral infection

Indexed keywords

ADENOVIRUS VECTOR; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; LATENT MEMBRANE PROTEIN 2; SYNAPTOTAGMIN I; CYTOMEGALOVIRUS MATRIX PROTEIN 65KDA; EBV ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN BARR VIRUS; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; MATRIX PROTEIN; PHOSPHOPROTEIN; T LYMPHOCYTE RECEPTOR;

ADENOVIRUS; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ALLOIMMUNITY; ANTIGEN SPECIFICITY; ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ADHESION; CELL EXPANSION; CELL ISOLATION; CELL KILLING; CELL SELECTION; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; LYMPHOCYTE DEPLETION; LYMPHOCYTE FUNCTION; MOLECULAR RECOGNITION; PHENOTYPE; PRIORITY JOURNAL; REPRODUCIBILITY; T LYMPHOCYTE ACTIVATION; TARGET CELL; CELL CULTURE; CELL PROLIFERATION; GENE VECTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN ADENOVIRUS; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; VIRUS INFECTION;

ADENOVIRUSES, HUMAN; CELL PROLIFERATION; CELLS, CULTURED; CYTOMEGALOVIRUS; DNA VIRUS INFECTIONS; GENETIC VECTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; PHOSPHOPROTEINS; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES, CYTOTOXIC; VIRAL MATRIX PROTEINS;

EID: 63849278776     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318181b4bd     Document Type: Article

References (29)

1. Bollard CM, Kuehnle I, Leen A, et al. Adoptive immunotherapy for posttransplantation viral infections. Biol Blood Marrow Transplant. 2004;10:143-155.
2. Fujita Y, Rooney CM, Heslop HE. Adoptive cellular immunotherapy for viral diseases. Bone Marrow Transplant. 2008;41:193-198.
3. Heslop HE, Brenner MK, Rooney CM. Donor T cells to treat EBVassociated lymphoma. N Engl J Med. 1994;331:679-680.
4. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: is T cell dose important in determining biological response? Bone Marrow Transplant. 1995;15:591-594.
5. Cobbold M, Khan N, Pourgheysari B, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med. 2005;202:379-386.
6. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 2002;99:3916-3922.
7. Gustafsson A, Levitsky V, Zou JZ, et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood. 2000;95:807-814.
8. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of genemodified virus-specific T lymphocytes. Nat Med. 1996;2:551-555.
9. Peggs KS, Verfuerth S, Pizzey A, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet. 2003;362:1375-1377.
10. Riddell SR, Watanabe KS, Goodrich JM, et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992;257:238-241.
11. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92: 1549-1555.
12. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038-1044.
13. O'Reilly RJ, Doubrovina E, Trivedi D, et al. Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants. Immunol Res. 2007;38:237-250.
14. Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006;12:1160-1166.
15. Feuchtinger T, Matthes-Martin S, Richard C, et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol. 2006;134:64-76.
16. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virusspecific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995;345:9-13.
17. Sili U, Huls MH, Davis AR, et al. Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy. J Immunother. 2003;26:241-256.
18. Yotnda P, Onishi H, Heslop HE, et al. Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene Ther. 2001;8:930-937.
19. Bollard CM, Straathof KC, Huls MH, et al. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother. 2004;27:317-327.
20. Leen AM, Sili U, Vanin EF, et al. Conserved CTL epitopes on the adenovirus hexon protein expand subgroup crossreactive and subgroup-specific CD8+ T cells. Blood. 2004;104: 2432-2440.
21. Bissinger AL, Rauser G, Hebart H, et al. Isolation and expansion of human cytomegalovirus-specific cytotoxic T lymphocytes using interferon-gamma secretion assay. Exp Hematol. 2002;30: 1178-1184.
22. Chatziandreou I, Gilmour KC, McNicol AM, et al. Capture and generation of adenovirus specific T cells for adoptive immunotherapy. Br J Haematol. 2007;136:117-126.
23. Feuchtinger T, Lang P, Hamprecht K, et al. Isolation and expansion of human adenovirus-specific CD4+ and CD8+ T cells according to IFN-gamma secretion for adjuvant immunotherapy. Exp Hematol. 2004;32:282-289.
24. Yvon ES, Vigouroux S, Rousseau RF, et al. Overexpression of the Notch ligand, Jagged-1, induces alloantigen-specific human regulatory T cells. Blood. 2003;102:3815-3821.
25. Bollard CM, Aguilar L, Straathof KC, et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med. 2004;200:1623-1633.
26. Gottschalk S, Edwards OL, Sili U, et al. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood. 2003; 101:1905-1912.
27. Leen AM, Sili U, Savoldo B, et al. Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications. Blood. 2004;103: 1011-1019.
28. Brosterhus H, Brings S, Leyendeckers H, et al. Enrichment and detection of live antigen-specific CD4(+) and CD8(+) T cells based on cytokine secretion. Eur J Immunol. 1999;29:4053-4059.
29. Bollard CM, Gottschalk S, Leen AM, et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007;110: 2838-2845.